Salvage radiation therapy guidelines for patients with prostate cancer recurrence need to be updated to include findings identified on PSMA PET, according to new research shared at SNMMI’s annual conference this week. 

The Detroit-based cancer institute achieved this landmark moment using the MRIdian A3i, which is the latest enhancement of the MRIdian system from ViewRay, Inc.

The team originally planned to enroll 300 men in the study, but the decisive results seen among the first 100 patients prompted them to cut enrollment in half.

Scans using a smaller dose were accurate when detecting lesions 0.5 cm or larger but more research into low-contrast lesions is still necessary, experts cautioned.

While the results offer indirect evidence, UCLA researchers said they support the clinical use of this technique for initial patient assessment.

Data presented this week at the annual meeting of the American Society for Radiation Oncology shines a light on the massive financial burden of prior authorizations.

Miami Cancer Institute experts found the technique "significantly" prolonged overall survival, sharing their findings at the European Society for Radiotherapy and Oncology 2021 conference.

Two Stanford University experts made their case for using molecular imaging to select patients for 177-Lu-PSMA-617 in a new Journal of Nuclear Medicine editorial.